Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Conditions

• Recurrent Chronic Lymphocytic Leukemia
• Recurrent Diffuse Large B-Cell Lymphoma
• Recurrent Follicular Lymphoma
• Recurrent Grade 1 Follicular Lymphoma
• Recurrent Grade 2 Follicular Lymphoma
• Recurrent Grade 3 Follicular Lymphoma
• Recurrent Grade 3a Follicular Lymphoma
• Recurrent Marginal Zone Lymphoma
• Recurrent Non-Hodgkin Lymphoma
• Recurrent Plasma Cell Myeloma
• Refractory Chronic Lymphocytic Leukemia
• Refractory Diffuse Large B-Cell Lymphoma
• Refractory Follicular Lymphoma
• Refractory Marginal Zone Lymphoma
• Refractory Non-Hodgkin Lymphoma
• Refractory Plasma Cell Myeloma
• Recurrent Mantle Cell Lymphoma
• Refractory Mantle Cell Lymphoma

Interventions

• BIOLOGICAL: Nivolumab

Sponsor

University of Washington

Collaborators

• [object Object]